搜索结果

Search Results for " megakaryocytes "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T13769	TA-316 Megakaryocytes/platelets inducing agent	Others	Others
	Megakaryocytes/platelets inducing agent being useful in treating diseases involving thrombopenia. Megakaryocytes/platelets inducing agent is an inducing agent for megakaryocytes and/or platelets from pluripotent stem cells.
T7417	Avatrombopag YM477,AKR-501,1-[3-氯-5-[[[4-(4-氯-2-噻吩基)-5-(4-环己基-1-哌嗪基)-2-噻唑基]氨基]羰基]-2-吡啶基]-4-哌啶羧酸,E5501	Thrombin; Thrombopoietin Receptor	Immunology/Inflammation; Proteases/Proteasome
	Avatrombopag (YM477) 是一种新型口服血小板生成素 (TPO) 受体激动剂，可激活 TPO 受体并增加巨核细胞增殖/分化和血小板生成。
T4570	Pipobroman Vercyte,A-8103,Amedel,哌泊溴烷	Others; DNA Alkylator/Crosslinker	DNA Damage/DNA Repair; Others
	Pipobroman (Vercyte) 是一种烷基化剂，是哌嗪的溴化衍生物。它通过抑制 DNA 和 RNA 聚合酶或减少嘧啶核苷酸掺入 DNA 发挥其作用。它在真性红细胞增多症和原发性血小板增多症中具有良好的临床活性，可用于癌症研究。
TP2342	Krds peptide Lys-arg-asp-ser
	Krds peptide is a synthetic tetrapeptide derived from lactotransferrin (residues 39 to 42) that suppresses binding of monoclonal antibody against glycoprotein IIb-IIIa on ADP-Stimulated platelets and megakaryocytes.
T40654	Avatrombopag hydrochloride AKR-501 hydrochloride,YM477hydrochloride,E5501hydrochloride
	Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC 50 of 3.3 nM. It effectively mimics the biological activities of TPO, stimulating platelet production by activating the intracellular signaling system and facilitating the generation of platelets and megakaryocytes from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 (CYP) 2C9 and CYP3A.
T68560	Totrombopag choline
	Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.
T68888	Avatrombopag maleate
	Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.